Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cardiol Therapeutics Inc T.CRDL.W.A


Primary Symbol: T.CRDL Alternate Symbol(s):  CRDL

Healthcare
Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive... see more

Recent & Breaking News (TSX:CRDL)

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Newsfile June 29, 2022

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT

Newsfile June 27, 2022

Cardiol Therapeutics Announces At-The-Market Equity Offering Program

Newsfile June 9, 2022

Market Movers. Today’s Top Stock Picks For New & Trending Opportunities

Stockhouse Editorial June 1, 2022

Market Movers. Today's Top Stock Picks For New & Trending Opportunities

Accesswire May 27, 2022

Cardiol Therapeutics (TSX:CRDL) appoints new directors

Shoran Devi May 19, 2022

Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors

Newsfile May 19, 2022

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis

Newsfile May 17, 2022

Cardiol Therapeutics Announces Year-End 2021 Update on Operations

Newsfile March 24, 2022

Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit

Newsfile March 22, 2022

Cardiol Therapeutics Appoints Jennifer M. Chao to Its Board of Directors

Newsfile March 15, 2022

Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial

Newsfile March 1, 2022

Cardiol Therapeutics (TSX:CRDL) appoints leaders in cardiovascular medicine to scientific advisory board

Julia Kennedy  January 19, 2022

Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board

Newsfile January 19, 2022

Cardiol Therapeutics (TSX:CRDL) closes US$50M public offering

John Ballem  November 5, 2021

Cardiol Therapeutics Announces Closing of US$50 Million Public Offering

Newsfile November 5, 2021

Cardiol Therapeutics Announces Pricing of Public Offering of Units

PR Newswire November 3, 2021

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units

PR Newswire November 2, 2021

Cardiol Therapeutics (TSX:CRDL) receives Health Canada approval for Phase II trial of CardiolRx

Julia Kennedy  October 25, 2021

Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

Newsfile October 25, 2021